C4 Therapeutics (CCCC) PT Lowered to $5 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.37 +2.12%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $5.00 (from $6.00) while maintaining a Underweight rating.
You May Also Be Interested In
- C4 Therapeutics unveils DNA-encoded library for molecular glue discovery
- Digital Realty Trust (DLR) PT Lowered to $227 at Freedom Broker
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
